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Virtually all smooth muscle genes analyzed to date contain two or
more essential binding sites for serum response factor (SRF) in their
control regions. Because SRF is expressed in a wide range of cell
types, it alone cannot account for smooth muscle-specific gene
expression. We show that myocardin, a cardiac muscle- and
smooth muscle-specific transcriptional coactivator of SRF, can ac-
tivate smooth muscle gene expression in a variety of nonmuscle
cell types via its association with SRF. Homodimerization of myo-
cardin is required for maximal transcriptional activity and provides
a mechanism for cooperative activation of smooth muscle genes by
SRF–myocardin complexes bound to different SRF binding sites.
These findings identify myocardin as a master regulator of smooth
muscle gene expression and explain how SRF conveys smooth
muscle specificity to its target genes.
Development of cardiac muscle, skeletal muscle, and smoothmuscle cells is accompanied by transcriptional activation of
overlapping but distinct sets of muscle-specific genes. Differen-
tiation of skeletal muscle cells is controlled by members of the
MyoD family of basic helix–loop–helix transcription factors,
which have the remarkable ability to activate skeletal muscle
gene expression when expressed in nonmuscle cell types (re-
viewed in refs. 1 and 2). No single factor has been found to be
sufficient to activate the cardiac muscle or smooth muscle gene
programs. Whether skeletal muscle is unique with respect to its
induction by a single transcription factor or whether as-yet-
unidentified master regulators govern cardiac muscle and
smooth muscle development remains to be determined.
Smooth muscle genes share the property of being regulated by
serum response factor (SRF), a ubiquitous MADS (MCM1,
Agamous, Deficiens, SRF) box transcription factor that binds as
a homodimer to the DNA consensus sequence CC(AT)6GG,
known as a CArG box (3, 4). Virtually every smooth muscle gene
analyzed to date contains at least two CArG boxes in its control
region, which act cooperatively to govern smooth muscle-specific
transcription (5–11). Blockade of SRF activity with a dominant
negative SRF mutant has also been shown to prevent expression
of smooth muscle genes in proepicardial explants (12). However,
the mechanism for SRF-dependent activation of smooth muscle
genes has not been fully resolved and is complicated by the fact
that SRF is not smooth muscle-specific.
Recently, we discovered an SRF transcriptional coactivator
called myocardin that is expressed specifically in smooth and
cardiac muscle cell lineages (13, 14). Myocardin belongs to the
SAP domain family of transcription factors (15) and activates
smooth and cardiac muscle reporter genes by interacting with
SRF (13, 14). Dominant negative myocardin mutants that com-
pete with the wild-type myocardin protein for interaction with
SRF block cardiac gene expression in injected Xenopus embryos
(13), suggesting an essential early role for myocardin in heart
development.
Here we show that myocardin is sufficient to activate the
program of smooth muscle differentiation. The promyogenic
activity of myocardin requires association with SRF and is
augmented by homodimerization, which provides a molecular
basis for the cooperativity among CArG boxes that is required
for smooth muscle gene activation.
Methods
Cell Culture and Transfection. 10T12 cells were maintained at low
density (30% confluence) in DMEM with 10% FBS. Trans-
fections were conducted with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Two days after
transfection, cells were shifted to differentiation medium
(DMEM with 2% horse serum). Five days later, further analyses,
including immunocytochemistry, Western blot, and RT-PCR,
were performed. Generally, 0.5 g of plasmid was used for each
well in a 12-well plate.
To obtain cardiac fibroblasts, neonatal rat hearts were
digested as described (16), and the fibroblast fraction was
purified by differential plating for 2 h on tissue culture plastic.
Adherent fibroblasts from this plating were passaged twice,
plated at low density (5  104 cells per cm2), and grown to
subconf luence in 10% FBS in DMEM. These cultures were
washed extensively to remove serum and infected with adeno-
viruses encoding lacZ or residues 128–935 of myocardin in
serum-free medium at a multiplicity of infection of 100 for 2 h
at 37°C. Cells were cultured for 14–21 days, fixed in 4%
formaldehyde in PBS for 30 min, and stained for smooth
muscle (SM)--actin as described below.
The PAC1 (17) and A10 (18) smooth muscle cell lines were
maintained in DMEM with 10% FBS and were infected with
adenovirus encoding lacZ or a myocardin dominant negative
mutant lacking the transcription activation domain (TAD) (13).
COS cell transfections and luciferase assays were performed
as described (13). Unless otherwise indicated, 100 ng of reporter
plasmid and 100 ng of each activator plasmid were used. The
total amount of DNA per well was kept constant by adding the
corresponding amount of expression vector without a cDNA
insert.
Myocardin and SRF expression vectors have been described
(13, 14). Myocardin mutants were generated through PCR-based
mutagenesis by using the QuikChange kit from Stratagene. All
mutations were confirmed by DNA sequencing. The myocardin
mutant NLS-basic contains an SV40 nuclear localization se-
quence (NLS) at the amino terminus and an internal deletion of
the basic region. The SV40 NLS is necessary for this mutant
protein to become localized to the nucleus. MyoD was expressed
by using the pcDNA3.1 expression plasmid (Invitrogen). The
SM22-luciferase reporter contained the 1434-bp promoter (6,
13, 14). The 3xc-fos-SRE-luciferase reporter was constructed by
linking three tandem copies of the c-fos serum response element
to a thymidine kinase promoter-driven luciferase reporter.
CMV-lacZ was included as an internal control for variations in
transfection efficiency.
Abbreviations: SRF, serum response factor; SM, smooth muscle; NLS, nuclear localization
sequence; MHC, myosin heavy chain; TAD, transcription activation domain; MRTF,
myocardin-related transcription factor.
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Immunocytochemistry and Western Blot. Immunostaining was per-
formed as described (19). Myogenic conversion assays were
performed as described (20), except that rabbit anti-SM-myosin
heavy chain (MHC) antibody was used. MF20 antisarcomeric
myosin antibody was collected from the supernatant of cultured
hybridoma cells from the Developmental Studies Hybridoma
Bank (University of Iowa, Iowa City). Mouse anti-skeletal
myosin (MY32), mouse anti-SM--actin (1A4), mouse anti-SM
calponin, mouse anti-h caldesmon, and mouse anti-SM myosin
light chain kinase (K36) were purchased from Sigma. Rabbit
anti-SM22 antibodies were provided by Drs. Michael Parmacek
(University of Pennsylvania, Philadelphia) and Lucia Schuger
(Wayne State University, Detroit). Rabbit anti-SM-MHC was
purchased from Biomedical Technologies (Stoughton, MA).
Mouse anti-SM--actin was purchased from ICN. All primary
antibodies were used at 1:200 dilutions, except for anti-SM--
actin, which was used at 1:1,000 dilution to avoid crossreaction
with SM--actin. FITC or Texas red-conjugated anti-mouse or
anti-rabbit secondary antibody (Vector Laboratories) was used
at a 1:200 dilution.
Fig. 1. Activation of smooth muscle cell differentiation by myocardin. (A) 10T12 cells were transfected with myocardin (a, b, e, f, and i–n) or MyoD (c, d, g,
and h) expression vectors and muscle markers were assayed by immunostaining. Bright and dark field images are shown in a, c, e, and g and b, d, f, and h,
respectively. FLAG-tagged myocardin was also detected within the nuclei of transfected cells in i–n. (B) 10T12 cells were transfected with expression vectors
encoding lacZ (as a negative control), myocardin, myocardin-NLSbasic, and MyoD. Protein extracts were assayed by Western blot by using antibodies against
SM22, SM--actin, and SM myosin light chain kinase. -Tubulin was detected as a loading control. (C and D) 10T12 cells (C) and NIH 3T3 or 3T3-L1 cells (D) were
transfected with the expression vectors indicated above each lane. RNA was isolated and muscle gene expression was assayed by RT-PCR. L7 was measured as
a loading control. (E) Primary rat cardiac fibroblasts were infected with adenoviruses encoding lacZ or myocardin and stained for SM--actin expression. Only
background staining was seen with Ad-lacZ, whereas intensely stained cells were seen with Ad-myocardin. The organization of these cells can also be seen at
low magnifications (Right). (Upper Right) A phase–contrast image. (Bars, 200 m.)
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Western blots on cell extracts were performed as described
(19) by using the antibodies described above in addition to an
anti--tubulin antibody (Sigma). As secondary antibodies,
horseradish peroxidase-conjugated donkey antibodies were
used.
Gel Mobility Shift Assays. Gel mobility shift assays were performed
as described (13). In vitro translated proteins and 32P-labeled
probe corresponding to the c-fos CArG box were used.
RT-PCR. Total RNA was isolated with TRIzol reagent (Invitrogen).
After treatment with DNaseI, 1 g of RNA was used as a template
for reverse transcription with random hexamer primers. Sequences
of PCR primers are available upon request. All PCR products span
intron regions of the genes. RT-PCRs were performed under
conditions of linearity with respect to input RNA.
Results
Activation of Smooth Muscle Gene Expression by Myocardin. Because
myocardin is expressed specifically in cardiac muscle and smooth
muscle cells and potently transactivates cardiac muscle and
smooth muscle reporter genes (13, 14), we tested whether it was
sufficient to activate endogenous muscle genes in transfected
10T12 fibroblasts. In parallel, we transfected cells with MyoD
(21) to compare the potential myogenic activity of the two
proteins.
Cells expressing myocardin adopted an elongated morphology
reminiscent of differentiated myocytes (Fig. 1A). MyoD-
transfected cells stained with MF20 antibody, which recognizes
cardiac and skeletal muscle myosin, but myocardin did not
induce these muscle markers. Instead, cells transfected with
myocardin stained intensely for expression of -SM actin. This
actin isoform is also expressed in cardiac myocytes, as well as in
skeletal muscle cells, as demonstrated by its up-regulation by
MyoD (Fig. 1 A). Myocardin also induced expression of SM22,
SM-calponin, h-caldesmon, SM myosin light chain kinase, SM
-actin, and SM-MHC proteins, which are markers of smooth
muscle (Fig. 1 A). Myocardin-induced expression of smooth
muscle proteins was further confirmed by Western blot analysis
(Fig. 1B). The activation of smooth muscle gene expression by
myocardin depended on reducing the concentration of FBS in
the medium from 10% to 2% horse serum, suggesting that cell
proliferation was unfavorable to its promyogenic activity.
We also measured the expression of smooth, cardiac, and skeletal
muscle markers by RT-PCR (Fig. 1C). Myocardin specifically
activated expression of smooth muscle markers in 10T12 cells,
whereas MyoD up-regulated expression of skeletal muscle markers
such as the acetylcholine receptor  subunit and embryonic MHC.
Neither myocardin nor MyoD activated expression of the cardiac
markers cardiac -MHC or atrial natriuretic factor (Fig. 1C).
Myocardin also induced the expression of smooth muscle
genes in NIH 3T3 cells and 3T3-L1 cells (Fig. 1D). In contrast,
HeLa cells and COS cells were refractory to the full promyo-
genic activity of myocardin (data not shown).
Because c-fos is also controlled by a CArG box, referred to as
the serum response element, we assayed its expression in myo-
cardin-transfected NIH 3T3 cells. Consistent with previous
studies showing that myocardin cannot activate a reporter gene
Fig. 2. Analysis of myocardin mutants. (A) Domains of myocardin required for smooth muscle gene expression. 10T12 cells were transfected with expression
vectors encoding the indicated myocardin constructs. Values are expressed as the number of SM-MHC-positive cells with each mutant relative to the number in
cultures transfected with the wild-type myocardin expression plasmid, which was assigned a value of 100. (B) Activation of smooth muscle gene expression by
myocardin and MRTF-A. 10T12 cells were transfected with expression vectors encoding myocardin, MRTF-A, or MRTF-B and scored for SM-MHC-positive cells
as in A. (C) Inhibition of smooth muscle gene expression by dominant negative myocardin. PAC1 and A10 cells were infected with adenovirus encoding lacZ or
the myocardin dominant negative mutant 128–513. Smooth muscle gene expression was assayed by RT-PCR. GAPDH was measured as a loading control.














linked to the c-fos promoter (13), there was no change in c-fos
expression in transfected cells (Fig. 1D).
We also expressed myocardin in rat primary cardiac fibro-
blasts. As shown in Fig. 1E, these cells showed robust expression
of -SM actin when infected with an adenovirus encoding
myocardin, whereas cells infected with a lacZ adenovirus were
negative for this and other smooth muscle markers (data not
shown). Intriguingly, cardiac fibroblasts that expressed ectopic
myocardin became organized into three-dimensional structures
resembling primitive vessels (Fig. 1E). We never observed these
sorts of structures in 10T12 cells expressing myocardin. The
potential significance of this morphological response remains to
be investigated.
Structure–Function Studies. The conserved N-terminal domain of
myocardin was dispensable, whereas the TAD was required for
generation of the smooth muscle phenotype, as shown by the lack
of myogenic activity of C-terminal deletion mutants lacking this
region (mutants 128–713 and 128–513; Fig. 2A). Replacement of
the myocardin TAD with that of the viral coactivator VP16
restored full myogenic activity, indicating that the TAD plays a
general role in transcriptional activation but does not confer
target gene specificity to the process. Deletion of the basic
region, which is required for SRF interaction (13), also abolished
myogenic activity of myocardin (mutant NLS-basic; Figs. 1B
and 2A), and mutation of the SAP domain reduced myogenic
activity (Fig. 2 A).
Myocardin shares high homology with two myocardin-related
transcription factors (MRTFs) A and B (14). MRTF-A was as
effective as myocardin in activating smooth muscle gene expres-
sion in 10T12 cells, whereas MRTF-B was inactive in this assay
(Fig. 2B).
To determine whether myocardin was necessary for smooth
muscle differentiation, we infected the PAC1 and A10 smooth
muscle cell lines, which express myocardin, with an adenovirus
encoding residues 128–513 of myocardin, which functions as a
dominant negative mutant (13, 14). The dominant negative
myocardin mutant specifically suppressed the expression of
smooth muscle genes by at least 5-fold in both cell lines (Fig. 2C).
We conclude that myocardin is sufficient for smooth muscle
differentiation and that a dominant negative myocardin mutant
can perturb the smooth muscle program.
Dimerization Is Required for Maximal Activity of Myocardin. Smooth
muscle genes generally require pairs of CArG boxes for tran-
scriptional activation (6–11), whereas the c-fos promoter, which
is activated by proliferative signals, contains only a single CArG
box. Although myocardin can form a ternary complex with SRF
on a single CArG box, it preferentially activates muscle genes
that contain multiple CArG boxes (13). Thus, there must be a
mechanism that enables myocardin to discriminate between
target genes based on the number of SRF binding sites.
To determine whether the selective responsiveness of multiple
CArG boxes to myocardin might reflect a requirement for
cooperative interactions of myocardin, we tested its ability to
self-associate. Indeed, immunoprecipitation experiments
showed that myocardin homodimerizes (Fig. 3A). Deletion
mapping localized the dimerization domain to residues 513–713,
which contain a coiled-coil motif resembling a leucine zipper
(Fig. 3B). Replacement of aliphatic residues at position 7 within
each heptad repeat in the putative leucine zipper with threo-
nines, which disrupts homodimerization of other leucine zipper
proteins (22), prevented myocardin dimerization (Fig. 3B) but
did not alter its ability to form a ternary complex with SRF
bound to the CArG box (Fig. 4A). The wild-type protein and
leucine zipper mutant yielded SRF ternary complexes with
Fig. 3. Homooligomerization of myocardin mediated by the coiled-coil domain. (A) Schematic of myocardin and myocardin deletion mutants. Deletion mutants
with FLAG tags and Myc-tagged myocardin were expressed in transfected COS cells. Cell extracts were immunoprecipitated (IP) with anti-FLAG antibody and
analyzed by immunoblot (IB) with anti-Myc antibody. Blots are shown (Right). LZ, leucine zipper. (B) The sequence of the leucine zipper region of myocardin
and the amino acid changes in the leucine zipper mutant (LZ-mut) are shown. Wild-type and LZ-mutant myocardin were expressed in COS cells, and
protein–protein interactions were detected by immunoprecipitation followed by immunoblotting, as indicated.
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identical mobilities, suggesting that myocardin binds SRF as a
monomer and that dimerization likely occurs between myocar-
din molecules bound to different CArG boxes. Despite its ability
to associate with SRF, the leucine zipper mutant was compro-
mised in its ability to activate CArG box-dependent promoters
and endogenous smooth muscle genes in 10T12 cells (Fig. 4
B–D), suggesting that dimerization is essential for maximal
activity of myocardin.
Discussion
Smooth muscle cells are essential for the contractility, structure,
and functions of the cardiovascular, pulmonary, digestive, and
genitourinary systems and express a unique array of muscle-
specific genes. Yet the molecular mechanisms that govern
smooth muscle gene expression are poorly understood. In this
study, we demonstrate that myocardin is sufficient to activate
smooth muscle genes in nonmuscle cells.
Myocardin Is a Master Regulator of SM Differentiation. The domi-
nant smooth muscle myogenic activity of myocardin is reminis-
cent of the activity of MyoD, which can convert nonmuscle cells
to skeletal muscle (1, 2, 21). Given that most, if not all, smooth
muscle genes contain essential CArG boxes in their control
regions (5–11), it is likely that myocardin activates these genes
directly through an obligate interaction with SRF. Consistent
with this conclusion, mutations in the SRF binding region of
myocardin abolish its myogenic activity, and myocardin is unable
to activate SRF-dependent reporter genes in SRF-deficient
embryonic stem cells (13, 14).
The embryonic expression pattern of myocardin is consistent
with its involvement in smooth muscle gene activation (13, 14).
Intriguingly, MRTF-A was also an effective activator of smooth
muscle gene expression, but its embryonic expression pattern
is not restricted to smooth and cardiac muscle cells (14). It is
unclear why smooth muscle genes are not expressed in many of
the cell types that express MRTF-A in vivo. Perhaps its level of
expression in these tissues is insufficient to activate the smooth
muscle program, or perhaps other factors or signals affect its
transcriptional activity. MRTF-B shares high homology with
myocardin and MRTF-A in the SRF binding region, but it was
ineffective in activating smooth muscle gene expression. Simi-
larly, MRTF-B is a weak SRF coactivator (14).
Myocardin and MRTF-A are the only transcription factors
shown to have the potential to activate the smooth muscle
differentiation program. If cofactors in addition to SRF are
required for this activity, they must be expressed in 10T12 cells,
or myocardin and MRTF-A must induce their expression. Over-
expression of the combination of SRF, GATA6, and LIM-
Fig. 4. Functional analysis of myocardin dimerization mutant. (A) Gel mobility shift assays were performed with in vitro translated SRF, myocardin (WT), and
the myocardin LZ-mutant and a radiolabeled probe corresponding to the c-fos serum response element. Only the region of the gel containing shifted probe is
shown. (B) COS cells were transiently transfected with expression vectors for myocardin and the myocardin LZ-mutant and luciferase reporters linked to the SM22
promoter or three copies of the c-fos CArG box, and luciferase activity was measured. (C) 10T12 cells were transfected with expression vectors for myocardin
or the myocardin LZ-mutant, and SM-MHC-positive cells were scored as in Fig. 2A. (D) 10T12 cells were transfected with expression vectors encoding myocardin
or the LZ-mutant. RNA was isolated and transcripts were assayed by RT-PCR.
Fig. 5. A model for the regulation of smooth muscle genes by SRF. Myocardin preferentially activates smooth muscle genes controlled by pairs of CArG boxes.
The c-fos promoter contains a single CArG box and is not efficiently activated by myocardin. Dimerization of myocardin through the leucine zipper (LZ) may
expose the TAD with resulting activation of muscle gene expression. Other promoter-specific factors (X) cooperate with SRF and myocardin.














domain proteins of the CRP family has been shown to stimulate
smooth muscle gene expression, apparently by enhancing SRF
DNA binding activity (23). However, none of these factors shows
myogenic activity alone. Two AT-rich DNA binding factors,
known as Mrf2 and Mrf2, have also been reported to activate
expression of early smooth muscle lineage markers characteristic
of myofibroblasts (24), but not the complete smooth muscle
program as observed with myocardin. Whether these factors
act downstream or in parallel to myocardin remains to be
determined.
A recent study reported that overexpression of myocardin in
skeletal and smooth muscle cells could elevate the expression of
-SM actin and calponin transcripts, as detected by RT-PCR
(25). Because skeletal muscle cells express some smooth muscle
genes at low levels, it was unclear from those findings whether
myocardin could induce the complete smooth muscle phenotype
in a nonmuscle cell. As this work was being completed, two other
studies also reported the ability of myocardin to activate smooth
muscle gene expression in mouse embryonic stem cells and
10T12 cells (26, 27).
The suppression of smooth muscle gene expression in the
PAC1 and A10 cell lines by a dominant negative myocardin
mutant suggests that myocardin is necessary for smooth muscle
differentiation. Although we favor the interpretation that this
mutant acts by preventing the formation of transcriptionally
active SRF–myocardin complexes, it is also possible that it acts
by another mechanism.
Preferential Activation Through Multiple CArG Boxes by Myocardin.
The number and positions of SRF binding sites and cofactor
associations confer specificity to the expression patterns of SRF
target genes. Transcriptional activation of smooth muscle genes
typically requires at least two CArG boxes that are often located
at a distance (5–11). In contrast, the c-fos gene is controlled by
one CArG box close to the transcription initiation site (28).
Because of the inability of myocardin to effectively activate
transcription through a single CArG box (13), such genes would
be expected to be exempt from the activity of myocardin.
Our findings demonstrate that the leucine zipper-like struc-
ture in myocardin mediates homodimerization and is required
for efficient activation of smooth muscle genes. We believe
dimerization occurs between myocardin proteins bound to SRF
homodimers on different CArG boxes, which would provide an
explanation for the dependence of smooth muscle genes on
multiple CArG boxes. We favor the possibility that dimerization
exposes the TAD of myocardin, which is otherwise cryptic (13),
or promotes the assembly of a transcriptional complex on muscle
target genes by juxtaposing distant CArG boxes in the vicinity of
the transcriptional machinery (Fig. 5). Selective interactions of
myocardin with other promoter-specific cofactors are likely to
provide further specificity to target gene activation.
Roles for Myocardin in Smooth Versus Cardiac Gene Expression. It is
notable that CArG boxes also control expression of many cardiac
and skeletal muscle genes that cannot be activated by myocardin
in transfected fibroblasts (29). Nevertheless, a dominant negative
myocardin mutant can suppress cardiac gene expression in
Xenopus embryos (13), suggesting that myocardin is required for
cardiac gene expression during embryogenesis, despite its in-
ability to activate cardiac gene expression in 10T12 cells.
Perhaps myocardin cooperates with other factors to control
cardiac gene expression in vivo, whereas in transfected fibro-
blasts it is only able to activate smooth muscle genes because of
the absence of essential cardiac cofactors or the presence of
negative regulators of cardiac genes that myocardin cannot
override.
Further understanding of the roles of myocardin and MRTFs
in smooth and cardiac muscle development will be provided by
the analysis of loss-of-function phenotypes in mice. It will also be
of particular interest to explore the potential involvement of
these transcriptional coactivators in smooth and cardiac muscle
disease.
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